Analysis of pediatric xylazine exposures highlights their rarity, suggesting a need for awareness among clinicians.
Based on National Poison Data System® data, pediatric xylazine-related exposures are relatively uncommon. Clinicians must remain vigilant for adulterants, including the possible re-emergence of xylazine, in the illegal drug supply.
No takes yet. Share an insight, caveat, or question.
Dernbach et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: